https://www.wsj.com/articles/glaxosmithkline-racing-to-provide-only-effective-covid-19-antibody-treatment-11642770001
GlaxoSmithKline PLC and partner Vir Biotechnology Inc. are straining
to meet soaring demand for their Covid-19 antibody treatment after the
highly mutated Omicron variant knocked out the two competing products.
Demand has jumped in recent weeks for the treatment, called
sotrovimab, because it is the only antibody drug authorized in the
U.S. for the newly infected that has been found to work against
Omicron.
No comments:
Post a Comment